174 related articles for article (PubMed ID: 11762357)
1. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors.
Baudin E; Bidart JM; Bachelot A; Ducreux M; Elias D; Ruffié P; Schlumberger M
Ann Oncol; 2001; 12 Suppl 2():S79-82. PubMed ID: 11762357
[TBL] [Abstract][Full Text] [Related]
2. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
[TBL] [Abstract][Full Text] [Related]
3. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience.
Stivanello M; Berruti A; Torta M; Termine A; Tampellini M; Gorzegno G; Angeli A; Dogliotti L
Ann Oncol; 2001; 12 Suppl 2():S73-7. PubMed ID: 11762356
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A measurement in neuroendocrine tumors.
Ferrari L; Seregni E; Martinetti A; Van Graafeiland B; Nerini-Molteni S; Botti C; Artale S; Cresta S; Bombardieri E
Int J Biol Markers; 1998; 13(1):3-9. PubMed ID: 9681293
[TBL] [Abstract][Full Text] [Related]
7. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.
Bernini GP; Moretti A; Ferdeghini M; Ricci S; Letizia C; D'Erasmo E; Argenio GF; Salvetti A
Br J Cancer; 2001 Mar; 84(5):636-42. PubMed ID: 11237384
[TBL] [Abstract][Full Text] [Related]
8. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
9. Metastatic neuroendocrine tumors to the thyroid gland mimicking medullary carcinoma: a pathologic and immunohistochemical study of six cases.
Matias-Guiu X; LaGuette J; Puras-Gil AM; Rosai J
Am J Surg Pathol; 1997 Jul; 21(7):754-62. PubMed ID: 9236831
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin A: its clinical value as marker of neuroendocrine tumours.
Nobels FR; Kwekkeboom DJ; Bouillon R; Lamberts SW
Eur J Clin Invest; 1998 Jun; 28(6):431-40. PubMed ID: 9693933
[TBL] [Abstract][Full Text] [Related]
11. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease.
Kidd M; Modlin IM; Mane SM; Camp RL; Shapiro MD
Ann Surg; 2006 Feb; 243(2):273-80. PubMed ID: 16432362
[TBL] [Abstract][Full Text] [Related]
12. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors.
Panzuto F; Severi C; Cannizzaro R; Falconi M; Angeletti S; Pasquali A; Corleto VD; Annibale B; Buonadonna A; Pederzoli P; Delle Fave G
J Endocrinol Invest; 2004 Jan; 27(1):6-11. PubMed ID: 15053236
[TBL] [Abstract][Full Text] [Related]
13. A comparison between three commercial kits for chromogranin A measurements.
Stridsberg M; Eriksson B; Oberg K; Janson ET
J Endocrinol; 2003 May; 177(2):337-41. PubMed ID: 12740022
[TBL] [Abstract][Full Text] [Related]
14. [Chromogranin A and neuroendocrine tumors].
Díaz Pérez JÁ; Currás Freixes M
Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
[TBL] [Abstract][Full Text] [Related]
15. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours.
Ferrari L; Seregni E; Bajetta E; Martinetti A; Bombardieri E
Anticancer Res; 1999; 19(4C):3415-27. PubMed ID: 10629629
[TBL] [Abstract][Full Text] [Related]
16. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors.
Kauhanen S; Seppänen M; Ovaska J; Minn H; Bergman J; Korsoff P; Salmela P; Saltevo J; Sane T; Välimäki M; Nuutila P
Endocr Relat Cancer; 2009 Mar; 16(1):255-65. PubMed ID: 19088184
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A assay in clinical practice.
d'Herbomez M; Do Cao C; Vezzosi D; Borzon-Chasot F; Baudin E;
Ann Endocrinol (Paris); 2010 Sep; 71(4):274-80. PubMed ID: 20538257
[TBL] [Abstract][Full Text] [Related]
18. Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas.
Børglum T; Rehfeld JF; Drivsholm LB; Hilsted L
Clin Chem; 2007 Mar; 53(3):438-46. PubMed ID: 17259235
[TBL] [Abstract][Full Text] [Related]
19. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors.
Ferrari L; Seregni E; Lucignani G; Bajetta E; Martinetti A; Aliberti G; Pallotti F; Procopio G; Della Torre S; Luksch R; Bombardieri E
Int J Biol Markers; 2004; 19(4):295-304. PubMed ID: 15646836
[TBL] [Abstract][Full Text] [Related]
20. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1.
Peracchi M; Conte D; Gebbia C; Penati C; Pizzinelli S; Arosio M; Corbetta S; Spada A
Eur J Endocrinol; 2003 Jan; 148(1):39-43. PubMed ID: 12534356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]